Cingulate INC Form 4 insider transactions

Laurie Myers, EVP and COO of Cingulate Inc., reports the acquisition of stock options in the company.

Cingulate Inc.'s Chief Executive Officer was granted a significant stock option award, according to a recent SEC filing.

EVP and Chief Medical Officer of Cingulate Inc., Matthew Brams, reports the acquisition of stock options.

Raul R. Silva, EVP and CSO of Cingulate Inc., reports the acquisition of stock options.

Cingulate Inc.'s SVP and CFO, Jennifer L. Callahan, was granted stock options as part of her 2024 bonus.

Raul R. Silva, EVP and CSO of Cingulate Inc., was granted stock options as part of his 2024 bonus.

Laurie Myers, EVP and COO of Cingulate Inc., was granted stock options as part of her 2024 bonus.

Cingulate Inc.'s CEO, Shane J. Schaffer, received 27,638 stock options as part of his 2024 bonus.

Cingulate Inc.'s EVP and Chief Medical Officer, Matthew Brams, was granted stock options as part of his 2024 bonus.

Raul R. Silva, EVP and CSO of Cingulate Inc., was granted 1,000 stock options on December 31, 2024.

Cingulate Inc.'s EVP and Chief Medical Officer, Matthew Brams, was granted 1,000 stock options on December 31, 2024.

Raul R. Silva, EVP and CSO of Cingulate Inc., reports the acquisition of stock options.

Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., reports acquisition of stock options.

Laurie Myers, EVP and COO of Cingulate Inc., reported the sale of 202 shares of common stock on August 15, 2024.

Raul R. Silva, EVP and CSO of Cingulate Inc., reports the acquisition of stock options.

Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., reports the acquisition of 1,000 stock options on June 28, 2024.

Director Peter J. Werth acquired stock options in Cingulate Inc. following stockholder approval of an amendment to the equity incentive plan.

Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc., reports the acquisition of stock options exercisable for 63,324 shares of common stock.

Cingulate Inc.'s CEO, Shane J. Schaffer, reports the acquisition of stock options in the company.

Jennifer L. Callahan, SVP and CFO of Cingulate Inc., was granted stock options for 94,986 shares on June 11, 2024, as disclosed in a Form 4 filing with the SEC.

Director John A. Roberts acquired stock options in Cingulate Inc. following stockholder approval of an amendment to the equity incentive plan.

Director Jeffrey S. Ervin reports acquisition of stock options in Cingulate Inc. following stockholder approval of an amendment to the equity incentive plan.

Laurie Myers, EVP and COO of Cingulate Inc., was granted stock options for 98,944 shares of common stock on June 11, 2024.

Director Bryan Jay Lawrence acquired stock options in Cingulate Inc. following stockholder approval of an amendment to the company's equity incentive plan.

Raul R. Silva, EVP and CSO of Cingulate Inc., was granted stock options for 63,324 shares on June 11, 2024, following stockholder approval of an amendment to the company's equity incentive plan.

Peter J. Werth, a director and 10% owner of Cingulate Inc., exercised pre-funded warrants to acquire common stock at nominal prices, increasing his indirect ownership through Werth Family Investment Associates LLC.

Raul R. Silva, EVP and CSO of Cingulate Inc., reports the acquisition of stock options.

EVP and Chief Medical Officer of Cingulate Inc., Matthew Brams, reports the acquisition of stock options.

Peter J. Werth, a director and 10% owner of Cingulate Inc., converted debt held by Werth Family Investment Associates LLC into pre-funded warrants to purchase shares of common stock.

Jennifer L. Callahan, SVP and CFO of Cingulate Inc., reports the purchase of common stock and warrants, reflecting a post-reverse stock split adjustment.